阿莫西林与莫西沙星治疗幽门螺杆菌胃病的临床疗效

谢志胜1，尚巧梅1 ，杨晓庆2

（1.陕西省榆林市榆阳区中医院，陕西 榆林，719000；2.陕西省铜川矿务局中心医院，陕西 铜川，727000）

浏览次数：152次 下载次数：461次

摘要：

目的 观察并分析阿莫西林与莫西沙星治疗幽门螺杆菌胃病的临床疗效。方法 随机选择2014年3月至2016年3月我院收治的幽门螺杆菌胃病患者80例为研究对象，并根据随机数字表法将其分为观察组与对照组，各40例。观察组患者采用莫西沙星治疗，对照组患者采用阿莫西林治疗。对比两组患者的临床疗效、HP根除率、耐药性以及不良反应发生率。结果 经过药物治疗，观察组与对照组的总有效率分别为97.50%，77.50%，两组比较，差异显著（P<0.05）；观察组的HP根除率为 92.50%，高于对照组的72.50%（P<0.05），且观察组耐药率为17.50%，低于对照组的42.50%（P<0.05）；观察组不良反应发生率为5.00%，明显低于对照组的20.00%（P<0.05）。结论 与阿莫西林相比，莫西沙星治疗幽门螺杆菌胃病的疗效更胜一筹，其能提高患者的HP根除率，降低耐药性与不良反应发生率，值得在临床治疗中广泛应用。

关键词：阿莫西林；莫西沙星；幽门螺杆菌胃病

中图分类号：R573文献标志码：A文章编号：2096-1413(2017)18-0031-02

Clinical efficacy of amoxicillin and moxifloxacin in the treatment of helicobacter pylori gastropathy
XIE Zhi-sheng 1, SHANG Qiao-mei 1, YANG Xiao-qing 2
(1.Yuyang District Hospital of Traditional Chinese Medicine, Yulin 719000, 2. Tongchuan Mining Bureau Central Hospital, Tongchuan 727000, China)

ABSTRACT: Objective To observe and analyze the clinical efficacy of amoxicillin and moxifloxacin in the treatment of helicobacter pylori gastropathy. Methods Eighty patients with helicobacter pylori gastropathy admitted and treated in our hospital from March 2014 and March 2016 were randomly selected as the research objects, all the patients were divided into observation group and control group according to random number table, with 40 cases in each group. The observation group was treated with moxifloxacin, while the control group was treated with amoxicillin. The efficacy, helicobacter pylori gastropathy eradication rate, drug resistance rate and incidence of adverse reaction between the two groups were compared. Results The total effective rate of the observation group and the control were respectively 97.50% and 77.50% , the difference between the two groups was significant (P<0.05). The helicobacter pylori gastropathy eradication rate of the observation group was 92.50% , which was significantly higher than 72.50% of the control group (P<0.05). The drug resistance rate of the observation group was 17.50%, which was lower than 42.50% of the control group (P<0.05). The incidence of adverse reaction of the observation group was 5.00%, which was significantly lower than 20.00% of the control group (P<0.05). Conclusion Compared with amoxicillin, moxifloxacin is more effective in the treatment of helicobacter pylori gastropathy, which can improve the eradication rate of HP and reduce the incidence of drug resistance and adverse reactions. It is worth to be widely used in clinical treatment.
KEYWORDS: amoxicillin; moxifloxacin; helicobacter pylori gastropathy

参考文献：
[1] 吴广,周玉生.用不同的药物治疗因幽门螺杆菌引发的胃部疾病的效果观察[J].当代医药论丛,2014,12(13):146.
[2] 曲桂霞.莫西沙星治疗幽门螺杆菌胃病114 例临床观察[J].中国民族民间医药,2015,24(12):76.
[3] 罗雪香,徐玉红,何剑琴,等.莫西沙星与阿莫西林治疗幽门螺杆菌相关性胃溃疡的疗效对比[J].中国药业,2015,24(16):64-65.
[4] 蔡锋.含莫西沙星四联疗法在幽门螺杆菌感染根除初次治疗中的临床疗效和不良反应[J].海峡药学,2016,28(7):123-124.
[5] 朱俊,樊锦河.埃索美拉唑镁、阿莫西林、莫西沙星联合铋剂根除幽门螺杆菌疗效观察[J].交通医学,2014,28(6):669-670.
[6] 谢秋云.阿莫西林与莫西沙星治疗幽门螺旋杆菌胃病的临床疗效及药理学分析[J].中国医院用药评价与分析,2016,16(1):173-174.
[7] 梁鹏.阿莫西林与莫西沙星治疗幽门螺杆菌胃病的疗效对比[J].临床医药文献杂志,2015,2(36):7408-7409.